Aesthetic Services Continue to Lead with Higher Redemptions; Gross Profit Doubled Year-on-Year
KUALA LUMPUR, 26 AUGUST 2025 – DC Healthcare Holdings Berhad (“DC Healthcare” or the “Group“), a medical aesthetic services provider specialising in the provision of non-invasive and minimally invasive procedures, today announced its financial results for the second quarter ended 30 June 2025 (“Q2 FY2025”). The Group posted a revenue of RM20.60 million, representing a 48% increase compared to RM13.88 million in the corresponding quarter of the previous year (“Q2 FY2024”).
The strong performance was driven primarily by higher redemption rates for aesthetic services and improved cash sales collection. The aesthetic segment contributed RM17.80 million, or 86% of total revenue, representing a 53% increase from RM11.65 million in Q2 FY2024. Gross profit doubled to RM10.45 million from RM5.19 million in Q2 FY2024, underscoring the Group’s enhanced service realisation and operational execution. Correspondingly, the Group narrowed its loss before tax (“LBT”) to RM1.03 million, a substantial improvement compared to the LBT of RM6.71 million recorded in the Q2 FY2024.
On a year-to-date basis, the Group recorded RM38.50 million in revenue for the first half of FY2025 (“1H FY2025”), a 65% increase from RM23.34 million in the first half of FY2024 (“1H FY2024”). Gross profit surged to RM19.57 million in 1H FY2025 compared to RM6.41 million in 1H FY2024, with LBT narrowing sharply to RM1.87 million in 1H FY2025 from RM14.62 million in 1H FY2024.
Quarter-on-quarter, the Group’s revenue rose 15% from RM17.90 million in the first quarter ended 31 March 2025 (“Q1 FY2025”) to RM20.60 million in Q2 FY2025, reflecting sustained demand and continued sales conversion. However, LBT was slightly higher at RM1.03 million compared to RM0.84 million in Q1 FY2025, primarily due to a one-off disposal of medical equipment which resulted in a RM0.70 million loss.
| Managing Director of DC Healthcare, Dr. Chong Tze Sheng (Link) |
Dr. Chong Tze Sheng, Managing Director of DC Healthcare commented, “Our second quarter results demonstrate the resilience of our business model, underpinned by strong consumer demand for aesthetic treatments and effective operational management. While we recorded a one-off disposal expense this quarter, the underlying fundamentals remain strong with topline growth and gross profit improvement. We will continue to focus on cost discipline, patient engagement, and expansion of our integrated brand ecosystem to drive sustainable growth.”
Looking ahead, DC Healthcare remains committed to several strategic pillars to reinforce its leadership in the aesthetic and wellness industry. The Group is synergising its core brands, Dr. Chong Clinic, Dr. Chong Slimming, and NewB Premium Skincare, while expanding its skincare product portfolio. Patient engagement is also being enhanced through artificial intelligence-assisted skin analysis and personalised treatment plans to optimise outcomes and retention.
Operational efficiency continues to be a key focus, with a Group-wide efficiency programme and the upcoming implementation of an enterprise resource planning (“ERP”) system aimed at optimising inventory control, resource allocation, and data-driven decision-making. Additionally, the Group had on 9 April 2025 announced a proposed acquisition of a three-storey end lot shop lot in Bandar Kinrara, Puchong, Selangor for RM8.0 million, which is expected to optimise its long-term operational costs by reducing reliance on leased office premises and support future expansion of its clinic network.
With these initiatives in place, DC Healthcare is well-positioned to capitalise on Malaysia’s growing aesthetic and wellness market, driving long-term value creation for stakeholders.
